Earnings blow for CSPC Pharma as the state drives a hard bargain
The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines Key Takeaways: CSPC Pharma…
AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt
Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Innogen Pharma jostles for a slice of the weight-loss market
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
